NUVL Company Profile and Key Details

Q: Who are the executives of NUVL?

Dr. Christopher D. Turner M.D.Chief Medical OfficerMr. Matthew MetivierVice President of HRDr. James R. Porter Ph.D.Chief Executive Officer, Pres & DirectorDr. Benjamin LaneSenior Vice President of Technical OperationsProf. Matthew D. Shair Ph.D.Founder, Head of Scientific Advisory Board & DirectorMs. Alex Balcom CPA, M.B.A.Chief Financial Officer & TreasurerMs. Darlene NociChief Devel. OfficerMr. Henry Pelish Ph.D.Senior Vice President of Drug DiscoveryMr. John Soglia Ph.D.Senior Vice President of Translational Devel.Ms. Deborah Ann Miller J.D., Ph.D.Chief Legal Officer & Sec.

NASDAQ : NUVL

Nuvalent

$123.96

At Close 4:00 PM

66.15

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Nuvalent, Inc. (NUVL) stock remained unchanged at $123.96 a share on NASDAQ. The stock opened at $123.96, fluctuating between $123.96 to $123.96 during the session.

Stock Snapshot

123.96

Prev. Close

9.13B

Market Cap

123.96

Day Low

-21.785588752196837

P/E Ratio

-5.69

EPS (TTM)

-1.6

Cash Flow per Share

123.96

Open

73.69M

Number of Shares

123.96

Day High

57.63%

Free Float in %

11.27

Book Value

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 14, 2026	123.97	123.99	123.95	123.96	3.07M
Jul 13, 2026	123.88	123.97	123.87	123.94	2.46M
Jul 10, 2026	123.89	123.91	123.85	123.90	2.06M
Jul 09, 2026	123.77	123.86	123.75	123.83	1.26M
Jul 08, 2026	123.73	123.85	123.73	123.80	1.16M
Jul 07, 2026	123.71	123.83	123.71	123.77	994.12K
Jul 06, 2026	123.70	123.78	123.55	123.72	1.31M
Jul 02, 2026	123.57	123.80	123.57	123.73	1.28M
Jul 01, 2026	123.56	123.63	123.50	123.60	1.31M
Jun 30, 2026	123.52	123.56	123.43	123.50	1.65M
Jun 29, 2026	123.56	123.58	123.46	123.51	1.24M
Jun 26, 2026	123.56	123.69	123.45	123.52	2.99M
Jun 25, 2026	123.57	123.67	123.51	123.53	1.18M
Jun 24, 2026	123.52	123.69	123.45	123.58	2.42M
Jun 23, 2026	123.49	123.52	123.41	123.44	1.34M
Jun 22, 2026	123.50	123.56	123.38	123.42	2.09M
Jun 18, 2026	123.40	123.56	123.30	123.43	4.41M
Jun 17, 2026	123.40	123.50	123.30	123.36	4.8M
Jun 16, 2026	123.41	123.47	123.29	123.39	2.16M
Jun 15, 2026	123.30	123.47	123.24	123.35	2.92M

Contact Details

Cambridge, MA 02142

United States

https://www.nuvalent.com 857 357 7000

About Company

Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.

Stock Peers

ARGX

-29.4-3.20%

argenx SE$888.82 REGN

11.16+1.70%

Regeneron Pharmaceuticals, Inc.$667.17 MDGL

6.74+1.24%

Madrigal Pharmaceuticals, Inc.$551.25 UTHR

-0.53-0.10%

United Therapeutics Corporation$527.94 VRTX

1.64+0.34%

Vertex Pharmaceuticals Incorporated$479.00 KRYS

16.63+4.96%

Krystal Biotech, Inc.$351.82 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ONC

BeOne Medicines AG$325.90 PRAX

-9.5-2.92%

Praxis Precision Medicines, Inc.$315.80 LGND

-3.03-1.01%

Ligand Pharmaceuticals Incorporated$297.50

Company Overview

The stock is currently trading near its 52-week high $71.13 and $123.99. With a market capitalization of about $9.13 billion, Nuvalent, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.14). Key stats such as the average daily volume over the past year has been around 2.33 million shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Nuvalent, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO James R. Porter, the company employs approximately 234 people and listed since July 29, 2021. Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer.

Technical Performance

NUVL has shown sold momentum, gaining 6.83% over the past week and 14.49% over the past quarter, though year-to-date performance is up 5.31%. Short-term trend indicators are mixed aligned (SMA20 0.76%, SMA50 0.41%, SMA200 16.26%). The stock’s 14-day RSI is 51.07 (neutral), while the ATR of 4.47 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -8.04% below its high and over 87.14% above its low.

Valuation Metrics

Nuvalent, Inc. trades at a P/E ratio of -20.46, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 8.3 trading at moderately above to book value. The P/FCF stands at -29.21, also below market averages.

Dividend & Fair Value

Nuvalent, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.60. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Nuvalent, Inc. generated EPS of -$5.32 over the past year. Five-year average earnings growth is -74.22%. Wall Street analysts project EPS growth of -2.52% annually over the next five years. The latest quarter delivered EPS of -$1.39. The next quarter is forecast at -$1.48. Next year's EPS is expected at -$33.16. Analyst sentiment is bullish. Analyst rating data shows there are 14 Strong Buy ratings, 10 Buy ratings, 10 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $189.00 to $105.00. The high target offers 52.47% upside. The low target suggests -15.3% downside. The mean target is $131.35. This offers 5.96% upside. Nuvalent, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 07, 2026, missed forecasts by 2.96%. The prior quarter beat by -12.84%. Over the last six quarters, Apple has recorded several small beats. These include 0.96% in February 27, 2025.

Shareholding & Insider Activity

Nuvalent, Inc. has 66.67 million shares outstanding. The public float is 41.56 million shares, elevated short interest at 17.88% of float. This equals 5.54 million shares. The short ratio is 11.1 days. Institutional investors hold 116.54% of the float. Insiders own 2.78%. Flynn James E holds 8.30 million shares, Hack Andrew A. F. has 1.45 million shares and Porter James Richard has 324.88 thousand shares. Over the past six months, insider transactions show net selling. They sold 127.44 thousand shares across 26 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Nuvalent has not generated any revenue. Returns are negative, with ROA at -17.23% and ROE at -18.02%.
On valuation metrics, Nuvalent trades at a P/E of -20.46, P/S of 0.00 and P/B of 8.30. The current ratio is 16.14 and quick ratio is 16.14.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Nuvalent posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Operating income was - $149.49M (margin 0.0%). Net income was- $126.22M (EPS - $2.17).
The company ended the quarter with $719.91M in cash and short-term investments, a total debt of $0.00, and net debt of - $335.39M. Total assets were $732.38M, with equity of $700.56M. Financials further reflected weakness, with operating cash flow of - $99.74M, free cash flow of - $99.74M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Nuvalent, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.45%, with price expected at $135.68 by July 28, 2026, within a range of $125.55 to $146.81 3-Month Outlook: Projected rise of 6.96%, reaching $132.59 by October 12, 2026, with a range of $131.00 to $134.20. 1-Year Outlook: Projected gain of 15.09%, with price at $142.67 by July 14, 2027, within a range of $138.11 to $147.09.

Key Takeaways

Nuvalent, Inc. (NASDAQ:NUVL) shares are flat 5.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Nuvalent, Inc. trading at a premium to the broader market with a P/E of -20.46. Analyst sentiment is cautious, with the majority of ratings in Market Perform territory and a mean price target of $115.25, suggesting -7.03% downside. Our AI forecast model points to short-term strength (9.45% over two weeks), a medium-term rise (6.96% over three months), and a longer-term gain (15.09% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Nuvalent, Inc. (NUVL) stock price?

Nuvalent, Inc. (NASDAQ: NUVL) stock price is $123.96 in the last trading session. During the trading session, NUVL stock reached the peak price of $123.96 while $123.96 was the lowest point it dropped to. The percentage change in NUVL stock occurred in the recent session was 0% while the dollar amount for the price change in NUVL stock was $0.00.

NUVL's industry and sector of operation?

The NASDAQ listed NUVL is part of Biotechnology industry that operates in the broader Healthcare sector. Nuvalent, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NUVL?

Dr. Christopher D. Turner M.D.
Chief Medical Officer
Mr. Matthew Metivier
Vice President of HR
Dr. James R. Porter Ph.D.
Chief Executive Officer, Pres & Director
Dr. Benjamin Lane
Senior Vice President of Technical Operations
Prof. Matthew D. Shair Ph.D.
Founder, Head of Scientific Advisory Board & Director
Ms. Alex Balcom CPA, M.B.A.
Chief Financial Officer & Treasurer
Ms. Darlene Noci
Chief Devel. Officer
Mr. Henry Pelish Ph.D.
Senior Vice President of Drug Discovery
Mr. John Soglia Ph.D.
Senior Vice President of Translational Devel.
Ms. Deborah Ann Miller J.D., Ph.D.
Chief Legal Officer & Sec.

How NUVL did perform over past 52-week?

NUVL's closing price is 74.27% higher than its 52-week low of $71.13 where as its distance from 52-week high of $123.99 is -0.02%.

How many employees does NUVL have?

Number of NUVL employees currently stands at 234.

Link for NUVL official website?

Official Website of NUVL is: https://www.nuvalent.com

How do I contact NUVL?

NUVL could be contacted at phone 857 357 7000 and can also be accessed through its website. NUVL operates from One Broadway, Cambridge, MA 02142, United States.

How many shares of NUVL are traded daily?

NUVL stock volume for the day was 0 shares. The average number of NUVL shares traded daily for last 3 months was 2.33M.

What is the market cap of NUVL currently?

The market value of NUVL currently stands at $9.13B with its latest stock price at $123.96 and 73.69M of its shares outstanding.

Employees	234
Beta	1.14
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

NUVL Company Profile and Key Details

Nuvalent

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Valuation Metrics

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Dividend & Fair Value

Earnings & Analyst Outlook

Key Takeaways

Price Forecast & Outlook